See original here: Aligos Therapeutics Doses First Subject in Phase 1 Proof-of-Concept Study of Small Molecule Drug Candidate ALG-000184 for Chronic Hepatitis B
See original here: Aligos Therapeutics Doses First Subject in Phase 1 Proof-of-Concept Study of Small Molecule Drug Candidate ALG-000184 for Chronic Hepatitis B
The rest is here: BioVie Interview to Air on Bloomberg International on the RedChip Money Report
Continued here: Jounce Therapeutics to Announce Third Quarter 2020 Financial Results and Host Conference Call on Friday, November 6, 2020
Original post: Nobilis Therapeutics to Present at CapCon 2020 Venture Conference
Continued here: MHRA Grants HAE Patients Early Access to BioCryst’s Berotralstat in United Kingdom
Visit link: Medexus Announces Engagement of Westmount Capital and Equity Incentive Grants to Insiders
Excerpt from: OliX Pharmaceuticals Announces FDA Clearance of the IND to Evaluate the Efficacy of OLX10010 in Phase 2a Clinical Trial for Hypertrophic Scars
Continue reading here:BioFlorida Names AIM ImmunoTech CEO Thomas K. Equels as Entrepreneur of the Year
Read more: Generex Subsidiary NuGenerex Immuno-Oncology Announces Appointment of Dr. Tamera Coyne-Beasley to the Scientific Advisory Board for its COVID-19...
Read this article: Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Clinical Trials of Setmelanotide in The Lancet Diabetes & Endocrinology
Recent Comments